louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01254929: F-18 PET Bone Scans Versus Tc-99m Bone Scans for the Diagnosis of Bone Metastases
Official title: 18F-Fluoride PET Bone Scans Versus Traditional 99mTc-MDP Gamma Camera Bone Scans for the Diagnosis of Bone Metastases: a Blinded, Prospective Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Bone Metastases
Keywords: Cancer
Bone metastases
Lead sponsor: Seattle Nuclear Medicine
Sponsor class: OTHER
First posted: 2010-12-07
Enrollment: 299
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who have cancer and have been referred for evaluation for bone metastases.

Brief summary: The purpose of this study is to compare 18F-Fluoride PET bone scans to traditional 99mTc-MDP bone scan to determine if one is better for diagnosing bone metastases.

Detailed description: Compare the diagnostic sensitivity, specificity, and accuracy of 18F-Fluoride PET bone scans versus traditional 99mTc-MDP bone scans for detecting bone metastases.

Determine if there is a significant change in clinical management between the two types of scans.

Measure and compare the number of equivocal or uncertain findings that would have caused additional testing, particularly additional imaging studies, to be performed for confirmation when using 18F-Fluoride PET bone scans versus 99mTc-MDP bone scans.

To quantify any adverse events resulting from either scan.

To perform subgroup analyses according to cancer cell type.

Eligibility criteria: Inclusion Criteria:

* Patient has cancer
* Has been referred for evaluation of bone metastases
* Patient or patient's legal representative can understand and consent to enrollment in the study
* Must be 18 years or older
* Can remain still during the scan (approximately one hour)
* Patient has Medicare

Exclusion Criteria:

* Patient does not have Medicare
* Under the age of 18
* Cannot lie still for the necessary time

Primary outcomes:
measure: Accurate identification of bone metastases
timeFrame: Upon study completion (2-3 years)
Secondary outcomes:
measure: Change in clinical management
timeFrame: Upon study completion (2-3 years)
measure: Determine if F-18 PET bone scans lead to fewer follow-up imaging studies.
timeFrame: Upon study completion (2-3 years)
measure: Quantify any adverse events from either type of scan.
timeFrame: Upon study completion (2-3 years)
measure: Perform subgroup analyses according to cancer cell type.
timeFrame: Upon study completion (2-3 years)
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Seattle Nuclear Medicine
state: Washington
Study officials:
affiliation: Seattle Nuclear Medicine
name: David Djang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02540629: Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Out-of-Hospital Cardiac Arrest
Keywords: Cardiopulmonary resuscitation
Emergency Medicine
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2015-09-04
Enrollment: 12670
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to improve the survival rate of out-of-hospital cardiac arrest patients by 2% through a bundle of three intervention measures including: 1) dispatcher-assisted CPR, 2) multi-tiered response team CPR, and 3) feedback CPR.

Detailed description: The project aims to implement gold standard emergency medical services (EMS) cardiopulmonary resuscitation (CPR) programs, which will result in increased bystander CPR, reduced EMS response time, and high quality CPR during prehospital resuscitation through a bundled approach including 1) dispatcher-assisted CPR (DA-CPR), 2) multi-tiered response team CPR, and 3) feedback CPR.

The DA-CPR program aims to contribute to improved bystander CPR rate and reduced EMS response time interval through rigorous monitoring of cardiac arrest detection at primary call receiving stage as well as increased number of dispatcher-assisted CPR instruction initiation in the target time of 90 seconds. The Team CPR protocol will render synergetic efforts among participating EMS personnel from both basic life support (BLS) and advanced life support (ALS) units within the new tiered dispatch system and subsequently deliver uninterrupted CPR to out-of-hospital cardiac arrest (OHCA) patients before hospital arrival. The feedback CPR monitoring and quality assurance program will contribute to high quality CPR delivered to the patients on the scene as well as during transport.

Eligibility criteria: Inclusion Criteria:

* EMS-assessed OHCA
* Cardiac etiology
* Above 15 years of age

Exclusion Criteria:

* Patients who do not receive EMS resuscitation
* Patients with signs of evident death (decapitation, evident livor mortis or rigor mortis)
* Do-Not-Resuscitate cases
* Pregnant patients
* Patients whom the mechanical devices cannot be applied to

Primary outcomes:
measure: Number of Participants With Survival to Hospital Discharge
timeFrame: At hospital discharge, up to 28 weeks from hospital admission
Secondary outcomes:
measure: Number of Participants With Good Neurological Recovery at Discharge
timeFrame: At hospital discharge, up to 28 weeks from hospital admission
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT02504229: DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Gastric Cancer
Lead sponsor: Beijing Biohealthcare Biotechnology Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2015-07-21
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with S-1 ((Tegafur, Gimeracil, and Oteracil Potassium) and oxaliplatin adjuvant chemotherapy in locally advanced unresectable or metastaticgastric cancer. Half of participants will receive DC-CIK combined with S-1 and oxaliplatin adjuvant chemotherapy,while the other half will receive S-1 and oxaliplatin adjuvant chemotherapy served as controls.


Eligibility criteria: Inclusion Criteria:

1. Age\>18y;
2. ECOG physical status 0-1;
3. The histologic diagnosis of stomach/gastroesophageal junction adenocarcinoma;
4. According to the RECIST 1.1 standard with measurable or evaluable lesion;
5. Accept swallow oral drug;
6. WBC≧4.0×10\^9/L;ALC≧0.8×10\^9/L;ANC≧1.5×10\^9/L;PLT≧100×10\^9/L;ALT,AST≦2.5 times of the normal limit;ALP≦2.5 times of the normal limit;TBIL﹤1.5 times of the normal limit;SCr﹤1 times of the normal limit;ALB≧30g/L;
7. The expected survival time of more than 3 months;
8. good compliance;
9. Provide written informed consent.

Exclusion Criteria:

1. Vital organs (heart,liver,kidney) function is serious dysfunction;
2. Patients received organ transplantation;
3. Patients with other malignant tumors or have occurred brain metastasis;
4. Patients with history of autoimmune disease;
5. Patients in pregnancy or breast-feeding period(women of child-bearing age need to check pregnancy test);
6. Patients with acute infection disease or in chronic active stage;
7. Patients with clear history of drug allergy or belong to allergic constitution;
8. Patients received chemotherapy,radiation therapy, immunosuppressive drugs (cyclosporine A,etc.) or other immune treatment in 4 weeks;
9. Patients received other clinical trials in 4 weeks.

Primary outcomes:
measure: Progression free survival
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese Academy of Medical Sciences Tumor Hospital
state: Beijing
Study officials:
affiliation: Chinese Academy of Medical Sciences Tumor Hospital
name: jinwan Wang
role: PRINCIPAL_INVESTIGATOR
affiliation: Chinese Academy of Medical Sciences Tumor Hospital
name: lin yang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01690429: Arousal Analysis by Pulse Wave Amplitude in Patients With Obstructive Sleep Apnea
Official title: Arousalanalyse Mittels Pulswellenamplitude Bei Patienten Mit Obstruktiver Schlafapnoe
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstructive Sleep Apnea
Keywords: Arousal detection
Pulse Wave Amplitude
Obstructive Sleep Apnea
Daytime sleepiness
Cardiorespiratory risk
Lead sponsor: Institut für Pneumologie Hagen Ambrock eV
Sponsor class: INDUSTRY
Collaborators: name: Weinmann Geräte für Medizin GmbH + Co. KG
First posted: 2012-09-21
Enrollment: 26
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Photoplethysmography is an easy non-invasive method to detect the pulse wave amplitude (PWA) from a finger. This can be measured using the Somnocheck micro system. A pulse wave amplitude decrease (PWAD) is considered to be a marker for autonomic activation. Detecting the PWAD is a surrogate marker for waking reactions (arousal) which eventually will contribute to assess sleep disruption and resulting performance deterioration. Arousal and performance deterioration and its possible improvement under continuous positive airway pressure (CPAP) therapy will be determined in this study.

Detailed description: Patients from the sleep laboratory with verified obstructive sleep apnea syndrome (OSAS) will be asked to participate in this study.

A device is used to determine autonomic arousal over night (SOMNOcheck micro). The Somnocheck micro records oxygen saturation as well as pulse frequency and breathing, and calculates an autonomic arousal index (AAI). Somnocheck measurements will take place in two nights (baseline and with CPAP) and parallel to a standard polysomnography (PSG). The PSG provides data to analyze the arousal frequency according to ASDA rules, which will then be compared to the AAI.

Performance is determined twice (prior and after CPAP therapy) by the use of a steering simulator programme (DASS). Differences in arousal will be correlated with differences in performance (deviation from the road, reaction time). The subjects are also asked to fill out the Epworth Sleepiness Scale (ESS) twice, prior and after therapy. Aim is to compare Somnocheck and PSG measurements and daytime sleepiness with DASS and ESS.

Eligibility criteria: Inclusion Criteria:

* Obstructive Sleep Apnea (AHI \>5)

Exclusion Criteria:

* Suspected acute cardiac, pulmonary or neurologic disease

Primary outcomes:
measure: pulse wave amplitude (PWA)
timeFrame: 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Hagen
country: Germany
facility: Helios Klinik Hagen
state: NRW
Study officials:
affiliation: Helios Klinik Hagen
name: Karl Heinz Rühle, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00786929: Acute Pancreatitis and Acute Fluid Collections
Official title: Randomized Controlled Trial on Sterile Fluid Collections Management in Acute Pancreatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pancreatitis
Keywords: Conversion to more aggressive treatment of recurrent fluid collection
Lead sponsor: University Medical Center, Tuzla
Sponsor class: OTHER
First posted: 2008-11-06
Enrollment: 63
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate if percutaneous drainage of sterile fluid collections recurring after initial aspiration in acute pancreatitis yielded better results than their conservative management.


Eligibility criteria: Inclusion Criteria:

* Symptoms and signs of acute pancreatitis and if pancreatic or/and peripancreatic fluid collections were confirmed by ultrasound and computed tomography examination

Exclusion Criteria:

* Collections resulting from pancreatic surgery, chronic pancreatitis and encapsulated collections and collections with uncertainty about the relationship between the collections and clinical symptoms and signs of acute pancreatitis were excluded.

Primary outcomes:
measure: Conversion to more aggressive procedure
timeFrame: Sep 2007
Secondary outcomes:
measure: Number of patients turning culture positive, length of hospital stay, catheter dwell time, catheter problems and changes per patient
timeFrame: Oct 2007
Other outcomes:
Locations:
city: Tuzla
country: Bosnia and Herzegovina
facility: University Clinical Center
state: TK
Study officials:
References:
citation: Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Ann Chir. 1993;47(6):537-41. No abstract available.
Clinical trial NCT01704729: The Children's WEAR Trial(Phase 1&2)
Official title: The Children's WEAR (Wearability and Evaluation of Adjustable Refraction) Trial(Phase 1&2)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myopia
Keywords: Myopia
Focus groups
refraction
Glasses
spectacles
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2012-10-11
Enrollment: 2300
Sex: ALL
Minimum age (years): 12
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Phase I: Focus groups on different designs of adjustable glasses and standard glasses (August-September 2012) Phase II: Two-month randomized trial comparing four groups: (September 2012 - August 2013)

Detailed description: Phase I: Focus groups on different designs of adjustable glasses and standard glasses (August-September 2012) Phase II: Two-month randomized trial comparing four groups: self-refraction with adjustable glasses, receiving custom standard glasses; subjective refraction by an expert refractionist after cycloplegic automated refraction and receiving custom standard glasses; subjective refraction by a rural refractionist after cycloplegic automated refraction, receiving custom standard glasses; and subjective refraction by an expert refractionist after cycloplegic automated refraction receiving ready made glasses (September 2012 - August 2013)

Eligibility criteria: Inclusion Criteria:

phase1: - aged 12-17 years

* with \<= -1.00D of myopic refractive error in each eye phase2: - 12-15 years old children from two locations in Guangdong Province
* with uncorrected vision \</= 6/12 in at least one eye thought to be due to refractive error (that is, correctable to at least 6/7.5 with cycloplegic subjective refraction by an optometrist)

Exclusion Criteria:

* those corrected VA can not up to 6/7.5 with cycloplegic subjective refraction by an optometrist
* those with significant strabismus or vision abnormality (keratopathy, cataract, vitreous macular diseases ), or with vision deficiency ( amblyopia ) children are to be excluded.
* Children developing acquired vision problems other than myopia

Primary outcomes:
measure: Visual acuity with and without study refractive correction
timeFrame: 2 months
Secondary outcomes:
measure: Self-reported and Supplemental visual functioning
timeFrame: 2 months
measure: frequency of glasses-wear and the reason why the frequency is low
timeFrame: 2 months
measure: Accuracy of spectacles given to children
timeFrame: 2 months
measure: Value attached to the glasses and satisfaction to the glasses
timeFrame: 2 months
Other outcomes:
measure: Breakage, damage and loss of spectacles
timeFrame: 2 months
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center
state: Guangdong
Study officials:
affiliation: Department of privetive ophthalmology,zhongshan ophthamic center,Sun Yat-sen University
name: Nathan G Congdon, MD,MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00482729: MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)
Official title: A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2007-06-05
Enrollment: 1246
Sex: ALL
Minimum age (years): 18
Maximum age (years): 78
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the efficacy and safety of an investigational treatment for type 2 diabetes mellitus.


Eligibility criteria: Inclusion Criteria:

* Patient has type 2 diabetes mellitus
* Patient is greater than or equal to 18 and less than or equal to 78 years of age on the day of signing the consent
* Patient has Hb1Ac greater than or equal to 7.5% and is appropriate for oral therapy
* Patient has not been on any antihyperglycemic agent (AHA) in the last 4 months
* Patient is a male, or a female who is unlikely to conceive

Exclusion Criteria:

* Patient has type 1 diabetes mellitus or history of ketoacidosis

Primary outcomes:
measure: Change From Baseline in Hemoglobin A1c (A1C) at Week 18
timeFrame: Baseline and Week 18
Secondary outcomes:
measure: Number of Patients With A1C < 7.0% at Week 18
timeFrame: Week 18
measure: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18
timeFrame: Baseline and Week 18
Other outcomes:
measure: Change From Baseline in A1C at Week 44
timeFrame: Baseline and Week 44
measure: Number of Patients With A1C < 7.0% at Week 44
timeFrame: Week 44
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Jul;13(7):644-52. doi: 10.1111/j.1463-1326.2011.01390.x.
citation: Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab. 2011 Sep;13(9):841-9. doi: 10.1111/j.1463-1326.2011.01416.x.
Clinical trial NCT00218829: DMSO-PDT of BCC - A 6 Year Follow up
Official title: Dimethylsulphoxide-supported Photodynamic Therapy of Basal Cell Carcinoma Combined With Curettage - A 6 Year Clinical and Histological Evaluation.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Basal Cell
Keywords: Photodynamic treatment
Basal cell carcinoma
DMSO
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
First posted: 2005-09-22
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to registrate long time clinical and histological treatment response of basal cell carcinoma (BCC) lesions treated with one or two procedures of dimethylsulfoxide supported 5-aminolaevulinic acid photodynamic therapy (DMSO-PDT).


Eligibility criteria: Inclusion Criteria:

* histological verified bcc.
* one or two PDT treatments with treatment interval no longer than two weeks.
* lesion complete response three months after therapy.

Exclusion Criteria:

* pregnant.
* Gorlin's syndrome.
* morpheaform or pigmented bcc.
* histology older than one year.
* tumour infiltration more than four mm.
* previous PDT treated lesions.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: St. Olav University Hospital, Trondheim
name: Eidi Christensen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Christensen E, Skogvoll E, Viset T, Warloe T, Sundstrom S. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol. 2009 Jan;23(1):58-66. doi: 10.1111/j.1468-3083.2008.02946.x. Epub 2008 Sep 18.
Clinical trial NCT02488629: Study of SCB01A in Patient With Head and Neck Cancer
Official title: An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Head and Neck Squamous Cell Carcinoma
Keywords: Head and neck squamous cell carcinoma
Lead sponsor: SynCore Biotechnology Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2015-07-02
Enrollment: 5
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and efficacy of SCB01A in head and neck cancer.

Detailed description: The study is designed to evaluate the safety and efficacy of SCB01A in patients with recurrent or metastatic squamous cell carcinoma in head and neck.

Eligibility criteria: Inclusion Criteria:

1. Confirmed squamous cell carcinoma of head and neck
2. Patients with nonresectable, unfeasible radiotherapy, recurrent or metastatic carcinoma, after previous treatment with platinum agent.
3. At least one measurable tumor lesion according to RECIST
4. Suitable Eastern Cooperative Oncology Group (ECOG) performance status
5. All eligible patients of childbearing potential have to use effective contraception
6. Signed informed consent before enrolment

Exclusion Criteria:

1. Receiving Chemotherapy, radiation therapy, major surgery or investigational agents
2. Severe pulmonary obstructive or restrictive disease
3. Uncontrolled inflammatory disease
4. Clinically significant cardiac disease
5. Results of laboratory tests
6. Pregnancy or nursing status
7. Known hypersensitivity to any component of SCB01A
8. History of exposure to SCB01A or its analogues
9. History of malignancy other than head and neck cancer
10. History of active or significant neurological disorder or psychiatric disorder
11. Any other reason the investigator deems the patient to be unsuitable for the study

Primary outcomes:
measure: Disease Control Rate (DCR)
timeFrame: 9 weeks from 1st administrationm drug
Secondary outcomes:
measure: To Assess the Overall Survival Rate
timeFrame: an expected average of 36 weeks
measure: To Assess the Progression-free Survival According to RECIST v.1.1
timeFrame: an expected average of 12 weeks
Other outcomes:
Locations:
city: Keelung
country: Taiwan
facility: Keelung Chang Gung Memorial Hospital & lovers lake branch
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei
country: Taiwan
facility: MacKay Memorial Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taoyuan
country: Taiwan
facility: Linkou Chang Gung Memorial Hospital
Study officials:
affiliation: SynCore Biotechnology Co., Ltd.
name: Hui-Hung Wang, MSc
role: STUDY_DIRECTOR
References: